Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. on April 15, 2021, covering events occurring on April 9, 2021, and April 15, 2021. The Company is an emerging growth company focused on allogeneic CAR T cell therapies.
Key Financial Metrics
- Cash Position: The Company expects to report approximately $193 million in cash and cash equivalents as of March 31, 2021. This figure is unaudited and preliminary.
- Transaction Costs: The Company agreed to an upfront payment of $20 million to reacquire rights from Servier. This consists of $1.25 million in cash and a waiver of $18.75 million in earned but unpaid milestones.
- Future Obligations: The agreement includes potential regulatory and commercial milestone payments and low- to mid-single-digit royalties on net sales for up to ten years.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the quarter ended March 31, 2021, noting that full financial results were not finalized at the time of filing.
Material Changes
The most significant change is the termination of the Development and Commercial License Agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier (Servier). Precision BioSciences has reacquired all global development and commercialization rights to its allogeneic CAR T candidates, including PBCAR0191 and PBCAR19B, as well as four other programs nominated by Servier. The Company now retains sole control over all activities for these programs.
Outlook, Management Commentary, and Risks
- Clinical Updates: Enrollment in the Phase 1/2a study for PBCAR0191 continues with a focus on dose level 3 following enhanced lymphodepletion. Initial response rates remain consistent with high rates reported in December 2020, and the safety profile is acceptable. Updated interim results are expected in mid-2021.
- Development Timeline: The Company expects to dose the first patient with PBCAR19B, its second CD19 allogeneic CAR T candidate, by the end of May 2021.
- Forward-Looking Statements: Management anticipates benefits from the reacquired rights but notes that future milestone payments and royalties depend on regulatory and commercial success. The filing includes standard risk factors regarding clinical trial outcomes and the uncertainties of forward-looking statements.
Investor Verification Checklist
- Verify the final audited cash balance for the quarter ended March 31, 2021, in the upcoming Form 10-Q.
- Review the full text of the Program Purchase Agreement (Exhibit to the 10-Q) for specific details on milestone triggers and royalty reduction clauses.
- Monitor the mid-2021 interim data release for PBCAR0191 to confirm durability of response under the enhanced lymphodepletion regimen.
- Confirm the actual dosing date for the first patient in the PBCAR19B study against the projected end-of-May 2021 timeline.